Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV)

被引：0
|
作者：
Lee Schwartzberg
Sally Y. Barbour
Gary R. Morrow
Gianluca Ballinari
Michael D. Thorn
David Cox
机构：
[1] West Clinic,Department of Pharmacy
[2] Duke University Medical Center,undefined
[3] University of Rochester School of Medicine and Dentistry,undefined
[4] Helsinn Healthcare SA,undefined
[5] Statistics Resources,undefined
[6] Inc.,undefined
[7] Eisai Inc.,undefined
来源：
Supportive Care in Cancer | 2014年 / 22卷
关键词：
Palonosetron; Serotonin antagonists; CINV; Nausea; Vomiting; Cancer chemotherapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：469 / 477
页数：8
相关论文
共 50 条
  • [31] Comparison of antiemetic efficacy and safety of palonosetron vs ondansetron in the prevention of chemotherapy-induced nausea and vomiting in children
    Patil, Veerendra
    Prasada, Harsha
    Prasad, Krishna
    Shenoy, Udyavar V.
    JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY, 2015, 13 (06): : 209 - 213
  • [32] Palonosetron (PALO), administered orally or intravenously (IV), plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting (CINV)
    Boccia, R. V.
    Gonzalez, E. F.
    Pluzanska, A. G.
    Clerici, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [33] NETUPITANT AND PALONOSETRON (NEPA), IS A COST-EFFECTIVE INTERVENTION FOR THE PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) IN SINGAPORE
    Lim, S. W.
    Loh, K. W. J.
    Boisseau, S.
    Ho, W. T.
    Qasuri, M.
    D'agostino, P.
    Turini, M. M.
    Bourhis, F.
    Eriksson, J.
    Hadjiat, Y.
    VALUE IN HEALTH, 2019, 22 : S475 - S476
  • [34] ANALYSIS OF PALONOSETRON VS ONDANSETRON IN PREVENTING CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) IN PEDIATRIC PATIENTS RECEIVING MODERATELY OR HIGHLY EMETOGENIC CHEMOTHERAPY (MEC/HEC)
    Kovacs, G.
    Wachtel, A. E.
    Basharova, E. V.
    Spinelli, T.
    Nicolas, P.
    Kabickova, E.
    PEDIATRIC BLOOD & CANCER, 2014, 61 : S108 - S108
  • [35] Clinical update on palonosetron in the management of chemotherapy-induced nausea and vomiting
    Celio, Luigi
    Denaro, Angela
    Canova, Stefania
    Gevorgyan, Arpine
    Bajetta, Emilio
    TUMORI JOURNAL, 2008, 94 (04): : 447 - 452
  • [36] A MULTI-CYCLE PHASE III STUDY EVALUATING PALONOSETRON VERSUS ONDANSETRON AT PREVENTING CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING IN PEDIATRIC PATIENTS RECEIVING
    Kovacs, G.
    Wachtel, A.
    Basharova, E.
    Spinelli, T.
    Nicolas, P.
    Kabickova, E.
    PEDIATRIC BLOOD & CANCER, 2015, 62 : S167 - S167
  • [37] The efficacy of palonosetron compared with granisetron in preventing chemotherapy-induced nausea and vomiting: A randomized study
    Kilickap, S.
    Kacan, T.
    Babacan, N. Akgul
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S272 - S272
  • [38] Phase III study of palonosetron for preventing chemotherapy-induced nausea and vomiting in pediatric patients
    Koga, Yuhki
    Kosaka, Yoshiyuki
    Koh, Katsuyoshi
    Matsumoto, Kimikazu
    Kumamoto, Tadashi
    Fujisaki, Hiroyuki
    Ishida, Yuji
    Suzuki, Ryoko
    Mochizuki, Shinji
    Goto, Hiroaki
    Yuza, Yuki
    Hara, Junichi
    ANNALS OF ONCOLOGY, 2021, 32 : S284 - S284
  • [39] Evaluation of daily breakthrough chemotherapy-induced nausea and vomiting (CINV) rates in a phase III study of NEPA versus an aprepitant (APR)/granisetron (GRAN) regimen
    Roeland, Eric
    Binder, Gary
    Ma, Joseph
    Lanzarotti, Corinna
    Zhang, Li
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (31)
  • [40] Prevention of delayed nausea and vomiting (D-CINV): Carryover effect analysis of pooled data from 2 phase III studies of palonosetron (PALO).
    Grunberg, SM
    Vanden Burgt, JA
    Berry, S
    Rubenstein, EB
    Berry, D
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 741S - 741S
12345